Avasimibe. CI 1011.
D000081:Acetamides; D000085:Acetates; D000818:Animals; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001055:Apolipoproteins B / Q000378:metabolism; D006224:Cricetinae; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors*; D013449:Sulfonamides; D013451:Sulfonic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000081:Acetamides; D000085:Acetates; D000924:Anticholesteremic Agents; D001055:Apolipoproteins B; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D013449:Sulfonamides; D013451:Sulfonic Acids; C423185:avasimibe; D002785:Sterol O-Acyltransferase